Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based
Benjamin P Levy1, Marc D Chioda2, Dana Herndon2
1Mount Sinai Health Systems, New York, New York, USA; Pfizer Oncology, New York, New York, USA; Cone Health Cancer Center, Greensboro, North Carolina, USA; Carolinas Pathology Group, Carolinas HealthCare System, Charlotte, North Carolina, USA; Chao Family Comprehensive Cancer Center, University of California at Irvine School of Medicine, Orange, California, USA; US Oncology Research, Ocala, Florida, USA; Carolinas HealthCare System, Charlotte, North Carolina, USA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; University of Colorado Cancer Center, Aurora, Colorado, USA belevy@chpnet.org.
Biomarker testing is crucial for non-small cell lung cancer (NSCLC) therapy selection. This study addresses challenges in tumor genotyping and tissue optimization to improve molecular testing practices for better patient care.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genomics
Background:
- Biomarker discovery has transformed non-small cell lung cancer (NSCLC) treatment selection.
- Tyrosine kinase inhibitors show significant efficacy in molecularly defined NSCLC patient cohorts.
- Genetic profiling is essential for personalized NSCLC therapy.
Purpose of the Study:
- To identify and address practical challenges in tumor genotyping for NSCLC.
- To clarify best practices for molecular testing in academic and community settings.
- To optimize tissue acquisition, processing, and testing for NSCLC biomarker analysis.
Main Methods:
- Review of challenges in implementing biomarker testing guidelines for NSCLC.
- Analysis of factors hindering successful tumor genotyping (e.g., data interpretation, resources).
- Convening of advisory boards to discuss and establish recommendations for best practices.
Main Results:
- Significant hurdles exist in performing comprehensive tumor genotyping in routine clinical practice.
- Physician-related factors (time, resources, multidisciplinary collaboration) impede optimal testing.
- Tissue quality and quantity present challenges for accurate molecular testing.
Conclusions:
- Addressing practical challenges is vital for widespread adoption of biomarker testing in NSCLC.
- Recommendations were developed to optimize tissue handling and molecular testing processes.
- A multidisciplinary approach is essential for integrating molecular profiling into NSCLC patient care.
